{"id":54643,"date":"2009-11-18T09:47:11","date_gmt":"2009-11-18T14:47:11","guid":{"rendered":"http:\/\/www.technologytransfertactics.com\/content\/?p=5308"},"modified":"2009-11-18T09:47:11","modified_gmt":"2009-11-18T14:47:11","slug":"tel-aviv-u-drug-may-slow-central-nervous-system-disorders","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/54643","title":{"rendered":"Tel Aviv U drug may slow central nervous system disorders"},"content":{"rendered":"

Working like an architect, Hagit Eldar-Finkelman, a professor in the department of human molecular genetics and biochemistry at Tel Aviv (Israel) University’s Sackler School of Medicine, is “building” a new drug — L803-MTS — to treat central nervous system (CNS) diseases such as Alzheimer’s. In preclinical studies, the compound also shows promise against Parkinson’s, Huntington’s, and diabetes. L803-MTS is based on the physical structure of the GSK3 protein, which plays a causative role in insulin resistance and type II diabetes. Working with chemists, biotechnologists, and 3-D modelists, Eldar-Finkelman and colleagues built — like engineers constructing a building — a drug that locks onto the GSK3 protein, rendering it harmless and unable to wreak havoc inside the body. Research findings on the L803-MTS drug have been published in the Journal of Molecular Biology<\/em><\/a> and Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics<\/em><\/a>.<\/p>\n

Since Eldar-Finkelman linked GSK3 to insulin resistance in diabetes more than 10 years ago, a race has been on among drug manufacturers to find a drug that can potentially turn off the harmful effects of the protein. Rather than build on existing drugs, Eldar-Finkelman and her colleagues worked from the ground up. “I decided to take a completely different approach from all the big drug companies rushing to find the ultimate drug,” Eldar-Finkelman says. “I designed my own.” Preclinical results have been positive, and the new drug does not exhibit dangerous toxic side effects — a problem with existing formulations. While L803-MTS cannot reverse the onset of a CNS disease, Eldar-Finkelman believes it can slow devastating effects such as memory impairment, depression, and insulin-resistance. With seed money from Ramot, the university’s TTO, she’s taken her basic research to the next step and is seeking a strategic partner to guide the research through the clinical process and eventual commercialization.<\/p>\n

Source: Science Daily<\/a><\/p>\n


<\/p>\n","protected":false},"excerpt":{"rendered":"

Working like an architect, Hagit Eldar-Finkelman, a professor in the department of human molecular genetics and biochemistry at Tel Aviv (Israel) University’s Sackler School of Medicine, is “building” a new drug — L803-MTS — to treat central nervous system (CNS) diseases such as Alzheimer’s. In preclinical studies, the compound also shows promise against Parkinson’s, Huntington’s, […]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-54643","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/54643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=54643"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/54643\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=54643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=54643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=54643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}